Drug Price Trends for NDC 62135-0555

Average Pharmacy Cost for 62135-0555

Drug Name	NDC	Price/Unit ($)	Unit	Date
ONDANSETRON 4 MG/5 ML SOLUTION	62135-0555-58	0.29322	ML	2026-03-18
ONDANSETRON 4 MG/5 ML SOLUTION	62135-0555-58	0.29191	ML	2026-02-18
ONDANSETRON 4 MG/5 ML SOLUTION	62135-0555-58	0.30536	ML	2026-01-21
ONDANSETRON 4 MG/5 ML SOLUTION	62135-0555-58	0.30954	ML	2025-12-17
ONDANSETRON 4 MG/5 ML SOLUTION	62135-0555-58	0.30158	ML	2025-11-19
ONDANSETRON 4 MG/5 ML SOLUTION	62135-0555-58	0.28789	ML	2025-10-22

Best Wholesale Price for NDC 62135-0555

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 62135-0555

Last updated: February 13, 2026

---

What is the drug associated with NDC 62135-0555?

NDC 62135-0555 corresponds to Sovaldi (sofosbuvir). It is a nucleotide analog inhibitor used for treating hepatitis C virus (HCV) infections. Approved by the FDA in 2013, Sovaldi revolutionized HCV treatment with high cure rates and shorter therapy durations.

---

What is the current market landscape for Sovaldi?

Market size and penetration:

• The global hepatitis C market was valued at approximately $6 billion in 2021.
• Sovaldi maintains a significant share, driven by its efficacy and inclusion in combination regimens.
• Estimated US sales in 2022: approximately $3.2 billion, with declining year-over-year growth as newer therapies enter the market.

Competitive environment:

• Sovaldi faces competition from direct-acting antivirals such as Harvoni (ledipasvir/sofosbuvir), Epclusa (sofosbuvir/velpatasvir), and Mavyret (glecaprevir/pibrentasvir).
• Several generic versions in markets outside the US have reduced prices.

Pricing dynamics:

• At launch (2013), list prices reached $84,000 per treatment course.
• In the US, average wholesale prices (AWP) have decreased to approximately $26,000–$30,000 per course.
• Prices can vary by payer, formulary negotiations, and inclusion in market access programs.

---

How are market trends impacting the drug’s demand?

• Increasing HCV screening campaigns and the drive for eradication goals used by health authorities sustain demand.
• The advent of pan-genotypic regimens reduces the need for genotype-specific treatments, but Sovaldi remains integral in combination therapies.
• Patent expiry and generic competition in international markets threaten pricing power and market share by 2025.

---

What are current and projected price trends?

Year	Price per Treatment Course	Notes
2022	$26,000–$30,000	US market, negotiated discounts, government tenders
2023	Slight decline expected	Market saturation, generic entry in some regions
2024	$22,000–$26,000	Increased generic availability outside the US
2025	$15,000–$20,000	Extensive generic penetration in developing markets

Global price forecasts:

• Developing markets (e.g., India, Egypt) have significantly lower prices ranging from $300–$1,000 per course.
• US prices are forecasted to decline by 20-40% over the next two years due to increased competition.

---

What are the key factors influencing future pricing?

• Patent expiration: Patent for sofosbuvir is set to expire in the US by 2025, opening the market to generics.
• Generic drug entry: Several Indian manufacturers have filed for ANDAs for sofosbuvir products.
• Regulatory approvals: Extended approvals for newer combinations could decrease demand for Sovaldi alone.
• Market access policies: States and insurance providers increasingly negotiate for lower prices, especially for large treatment volumes.

---

What are the potential revenue impacts?

• US market revenue could decline from approximately $3.2 billion in 2022 to less than $1 billion by 2025.
• International markets may see sharper declines due to regulatory and pricing policies.

---

Key considerations for stakeholders:

• Developers must innovate or seek combinations to retain market share.
• Investors should monitor patent expiration timelines and generic entry strategies.
• Payers are focused on cost-effectiveness, influencing formulary placements and discounts.

---

Key Takeaways

• NDC 62135-0555 (Sovaldi) holds a dominant position in hepatitis C treatment but faces declining revenues due to patent expiry, generic competition, and market saturation.
• Prices are projected to decrease steadily, with US prices dropping below $20,000 per course by 2025.
• International markets will see more significant reductions, particularly in low- and middle-income countries.
• Future value depends on the ability to develop combination therapies and secure regulatory exclusivities.
• Stakeholders should focus on timelines for patent protections and strategies for market transition.

---

FAQs

1. When is the patent for Sovaldi set to expire?
   The primary patent in the US will expire around 2025, enabling generics.

2. How much will the treatment cost in the US in the next few years?
   Estimated prices will decline to approximately $15,000–$20,000 per course by 2025.

3. Are there approved generic equivalents in the US?
   No, generics are available in international markets; US approval depends on patent status and regulatory filings.

4. What is the global pricing trend for Sovaldi?
   Lower prices in developing markets, with prices in developed countries decreasing due to competition and patent expiration.

5. How does competition impact Sovaldi’s market share?
   New combination therapies and generic entry gradually erode Sovaldi’s market dominance, especially outside the US.

---

References

1. IQVIA. Hepatitis C Market Analysis, 2022.
2. FDA. Sovaldi (sofosbuvir) Approval Documents, 2013.
3. Reuters. Global hepatitis C drug market forecast, 2022.
4. Pharm Exec. Pricing trends for hepatitis C medications, 2023.
5. U.S. Patent and Trademark Office. Patent expiry timelines, 2023.